Published in Cardiovascular Week, November 6th, 2006
Study 1: Defibrillation threshold reassessment after the institution of antiarrhythmic drug therapy in patients with implanted cardioverter defibrillators (ICDs) is not routinely required.
According to recent research from Germany, "Many patients with ICDs receive adjunctive antiarrhythmic drug therapy, most commonly amiodarone or sotalol. The effects of these drugs on defibrillation energy requirements have not been previously assessed in a randomized controlled trial. The Optimal Pharmacological Therapy in Cardioverter Defibrillator...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.